China Resources Pharmaceutical Group's quarterly market cap
declined
from Dec. 2024 (€4,272 Mil) to Jun. 2025 (€3,393 Mil) and
declined
from Jun. 2025 (€3,393 Mil) to Dec. 2025 (€3,003 Mil).
China Resources Pharmaceutical Group's annual market cap
increased
from Dec. 2023 (€3,644 Mil) to Dec. 2024 (€4,272 Mil) but then
declined
from Dec. 2024 (€4,272 Mil) to Dec. 2025 (€3,003 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. China Resources Pharmaceutical Group's Enterprise Value for Today is €16,956 Mil.
China Resources Pharmaceutical Group (STU:640) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
China Resources Pharmaceutical Group Market Cap Related Terms
China Resources Pharmaceutical Group Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group Market Cap Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Pharmaceutical Group Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's Market Cap distribution charts can be found below:
* The bar in red indicates where China Resources Pharmaceutical Group's Market Cap falls into.
China Resources Pharmaceutical Group Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group (STU:640) has a Market Cap of €3,166 Mil as of Jul. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on China Resources Pharmaceutical Group and its competitors. According to the industry distribution chart, China Resources Pharmaceutical Group ranks #98 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 9.6%.
Is China Resources Pharmaceutical Group's Market Cap too high?
China Resources Pharmaceutical Group's current Market Cap is €3,166 Mil. Based on the distribution chart, China Resources Pharmaceutical Group ranks #98 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Resources Pharmaceutical Group has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Pharmaceutical Group ranks #98 out of 1024 companies for Market Cap. This places China Resources Pharmaceutical Group in the top 10% of its industry — outperforming the majority of peers. The industry median Market Cap is 217.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 217.83, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on China Resources Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Market Cap is 217.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Pharmaceutical Group's current Market Cap is €3,166 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.64, compared to a current price of €0.49 — trading 24.1% below its estimated fair value. The current Market Cap is €3,166 Mil. China Resources Pharmaceutical Group's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current Market Cap is €3,166 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.49 is trading 24.1% below its estimated GF Value™ of €0.64.
GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for STU:640:
Market Cap: €3,166 Mil
GF Value™: €0.64 vs. price of €0.49 (24.1% below fair value)
No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Pharmaceutical Group Business Description
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
63GF Score
Get the complete analysis for STU:640
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:640 has been successfully added to your 
